Mangold Insight publishes company analysis of Cyxone

Report this content

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that an analysis of the company has been published by Mangold Insight.

The company analysis was published on Tuesday, September 10, 2019. Mangold Insight has taken into account the company's potential for the next 12 months. The report can be read in its entirety in Swedish only on the company's website.

Cyxone AB (publ)

Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
Adelgatan 21

211 22 Malmö, Sweden

About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I and Rabeximod for RA in clinical phase II-program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, 



Documents & Links